Order a test

Helping you make informed decisions and formulate effective treatment plans

More about RGCC

Information for patients

We work with your healthcare provider to deliver a range of personalised tests so you can choose the best treatment together.

More patient information

Stay tuned for RGCC's Cancer App Version 2.0 Coming Soon!

Cancer Tests

New methods and reliable tests to help deliver personalised treatment


Onco-D-clare is a cancer screening test based on the interaction of molecular biology with machine learning algorithms. This screening test can help detect cancer before symptoms appear.  Peripheral blood mononuclear cells are isolated from blood samples, and gene expression analysis is performed in more than 90 genes. Their expression profile is then used for the […]

View test

InVyomma Plus

InVyomma Plus focuses on gut microbiome profiling, including analysis of short-chain fatty acids, and how they are associated with cancer. It has been discovered that the microbiome is closely related to the occurrence and development of a variety of cancer types in the epithelial barrier and sterile tissues. Symbiotic ecosystems that inhabit the gut or […]

View test

Onconomics Extracts+

Onconomics Extracts+ provides highly detailed and accurate information about how effective specific natural substances and plant extracts are, as anticancer agents as well as the gene expression profile of genes, associated with fundamental biological processes. This includes processes such as angiogenesis, cell cycle regulation, self-repair, metastasis, apoptosis, proliferation etc. Circulating tumor cells are isolated from […]

View test


RGCC CAMBISeq® is an innovative test that uses next-generation sequencing analysis on both DNA and RNA to provide clinicians with crucial insight into cancer.

View test

Array comparative genomic hybridisation (aCGH) RGCC

The array comparative genomic hybridisation (aCGH) RGCC test is used to identify chromosomal abnormalities in a patient that could lead to cancer.

View test


Immune-Frame is used to assess the condition of a patient’s immune system. Scientists use the test to identify specific cellular markers that are responsible for switching a patient’s immune system on and off.

View test

Metastat RGCC

Metastat RGCC is an advanced test to detect specific blood-borne markers that can accurately determine whether a secondary cancerous tumour is likely to develop and its potential location.

View test


ChemoSNiP is an innovative test that uses an advanced scientific technique called pharmacogenomics to analyse how a patient’s body will respond to a specific drug.

View test

Oncocount RGCC

Oncocount RGCC detects the presence of circulating tumour cells (CTCs) and their concentration in the blood.

View test

Onconomics Extracts

Onconomics Extracts is a unique and highly detailed test that provides information on how effective natural substances and plants extracts are at attacking circulating cancer cells (CTCs).

View test

Onconomics Plus RGCC

Onconomics Plus RGCC provides information about the effect of specific anti-cancer drugs, targeted therapies and natural treatments on the cancer cells in an individual patient.

View test

Onconomics RGCC

Onconomics RGCC provides highly detailed and accurate information about how effective specific anti-cancer drugs and targeted therapies are in treating cancer.

View test
See all RGCC tests

Use our ‘smart filter’ to identify which test is best for your patients

Find out more

News & Events

Find out more about our latest research, trials and education days.

RGCC Unveils Revolutionary Cancer Detection Test, Onco-D-clare

RGCC announces the launch of Onco-D-clare, a groundbreaking cancer detection test that marks a significant milestone in early cancer screening. Utilizing the cutting-edge technology of molecular biology coupled with artificial neural networks, this innovative test empowers individuals to detect cancer before symptoms manifest. Onco-D-clare operates by isolating peripheral blood mononuclear cells from blood samples, followed […]

Read more

Top 10 Swiss Biotech Company 2023

We are delighted to announce that RGCC has received prestigious recognition as one of the top 10 Swiss Biotech companies in 2023 by Life Sciences Review. Proudly standing alongside Switzerland’s esteemed biotech leaders, this acknowledgment underscores our unwavering commitment to innovation, excellence, and our continual contribution to the life sciences sector. It also reflects our […]

Read more

Recap: RGCC Malaysia Conference 2024 – Advancing Cancer Care in Southeast Asia

In March 2024, RGCC, in collaboration with SOL Integrative Wellness Centre, hosted its inaugural Malaysia Conference in Kuala Lumpur, marking a significant step forward in revolutionizing cancer care in the Southeast Asia region. From 9-10 March, healthcare practitioners from both integrative and conventional oncology gathered to explore the latest advancements in personalized testing, case studies, […]

Read more

RGCC Hosts Successful DACH Doctor’s Day in Germany, March 2024

We are excited to announce the successful conclusion of the RGCC Doctor’s Day of the DACH area, “Ärztetagung” in Bavaria, Germany, held from 1-2 March. This event served as a platform for doctors and medical practitioners to stay updated on the latest company developments, products, and technologies. Attended by approximately 20 dedicated medical practitioners, the […]

Read more

RGCC International Gathering Event 2023

RGCC International GmbH recently concluded its highly anticipated Gathering at “The Circle Convention Centre Zurich Airport” in Switzerland from 8-10 September 2023. The Gathering held both online and in person, marked a significant milestone for RGCC, bringing together over 100 collaborators from around the globe. During the event, attendees were granted exclusive access to the […]

Read more

Global Presence

RGCC operates in 23 countries across the world, with bases in all five continents.

Find out more